Vaccine maker Cargill announced today that the US market has seen record-high numbers of children who were fully vaccinated for the vaccine and the company is looking to increase that market.

The US market for the Cargills Cargillin vaccine has grown from more than 10 million in early 2018 to more than 12 million now.

That is an increase of more than 60 percent in the last year alone.

Cargilling said in a statement that the company has seen its sales of the Cefazolin vaccine rise from $5.4 billion in 2018 to $8.2 billion in 2019.

The Cargilled Cefaloxacin vaccine is made by the company in Fort Worth, Texas.

Its manufacturer, Merck, has also expanded its vaccine production capacity to include two other vaccines: the Gardasil and Cervarix vaccines.

Cefasil is made in Mexico and Cevapax is made for use in the US.

Cefazollins vaccine is available in the United States and Canada.

Cesca, the Spanish manufacturer of Gardasill, announced in December that it is expanding its vaccine manufacturing capacity to add another 7.4 million doses of its Cefalo vaccine in 2018.

The company also announced that it plans to launch a Cefarix and Cefaviren vaccine in the U.S. in early 2019.